Valuation: NetraMark Holdings Inc.

Market Cap 75.7M 53.96M 46.91M 43.66M 40.09M 5.15B 76.88M 515M 202M 2.56B 203M 198M 8.6B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 75.7M 53.96M 46.91M 43.66M 40.09M 5.15B 76.88M 515M 202M 2.56B 203M 198M 8.6B EV / Sales 2026 *
189x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
07-10 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-30 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-15 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-08 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-10 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
03-25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
03-25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
03-25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 53.96M
+3.02%+21.75%-11.33%+41.90% 3,451B
+0.65%+0.11%-20.23%+548.71% 295B
-0.22%+8.55%+97.62%+150.84% 95.39B
+2.16%+4.22%-4.75%+48.65% 93.64B
+4.41%+4.09%-37.16%-11.88% 74.44B
+0.47%+6.74%-30.78%+72.94% 65.38B
-1.82%+4.87%+10.13%+65.00% 45.42B
+6.38%+3.97%-24.05%-43.77% 30.53B
+3.36%+3.08%+62.88%+223.63% 29.95B
Average +2.37%+6.03%+4.70%+121.78% 464.51B
Weighted average by Cap. +1.89%+18.51%-9.42%+80.76%

Financials

2026 *2027 *
Net sales 401K 286K 248K 231K 212K 27.28M 407K 2.73M 1.07M 13.58M 1.07M 1.05M 45.54M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise